Category: Guest content

Biotech in Countries Starting with “I” – Part 11: Italy (secondo)

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. The run-up to Christmas in Italy is a magical experience, and a great time to revisit Italian agricultural biotechnology. Readers of this irregular series may recall an earlier entry on […]


Click here for reuse options!
Copyright 2016 Biotechblog

Which drug makers do a good job getting poor patients access to their medicines?

The pharmaceutical industry is regularly chastised for failing to do enough to ensure that people in low and middle-income countries have access to its medicines. Yet the real picture is actually more nuanced, according to a newly released report that finds some – but not all – drug makers are making headway. Some companies, for […]



Addressing the Challenges of Pharmaceutical Distribution in International Markets

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below. If domestic pharmaceutical distribution is complex, international distribution is considerably more complicated International growth markets for pharmaceuticals represent enormous opportunities, but they also bring their own unique challenges, including infrastructure, fragmented distribution, and a patchwork […]


Click here for reuse options!
Copyright 2016 Biotechblog

Addressing the Challenges of Pharmaceutical Distribution in the United States

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below. Pharmaceutical distributors face significant supply chain challenges Designing, implementing, and managing efficient product distribution can present pharmaceutical distributors and wholesalers with opportunities to create a long term strategic advantage. Distribution of pharmaceuticals has always been […]


Click here for reuse options!
Copyright 2016 Biotechblog

Treat pharma as a utility, and 10 other ways states can lower drug prices

As prescription drug costs continue to squeeze state budgets, a group of state health policy makers is offering some novel – and also some familiar – suggestions for coping. These include regulating the pharmaceutical industry as a utility, allowing states to operate as pharmacy benefit managers and waiving some provisions of the Medicaid program. In […]



Process Validation and Its Need in the Biotechnology Industry

process-validation

This is a guest post from Edward Simpson, a seasoned calibration and technical engineer. Do you have a response to Edward’s post? Respond in the comments section below. Process validation is a crucial component of cGMP (current Good Manufacturing Practice) in industries concerned with public health and safety, such as pharma, bio-pharma and biotech.  What […]


Click here for reuse options!
Copyright 2016 Biotechblog

Making sense of drug names

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below. A drug by any other name would work just as well… In William Shakespeare’s play Romeo and Juliet, Juliet uses the phrase “A rose by any other name would smell just as sweet” to argue […]


Click here for reuse options!
Copyright 2016 Biotechblog

Formulary Best Practice: Cost Containment through Generic Drugs

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below. Effects of generic competition in pharmaceuticals are more complex than they used to be Cost containment has been a major aspect of the Affordable Care Act (ACA), with incentives for reducing hospital readmissions and pressure […]


Click here for reuse options!
Copyright 2016 Biotechblog

Branding Biotech – Communicating the Brand’s Point of Differentiation

This is a guest post from Brannon Cashion, President of Addison Whitney Health. Do you have a response to Brannin’s post? Respond in the comments section below. The branding process in the biotech sector can be related to the oxymoronic term of “new and improved.” While there is great benefit to being new, and also to […]


Click here for reuse options!
Copyright 2016 Biotechblog

Biosimilar Naming: Distinguishable or Disingenuous?

This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a member of the Alliance for Patient Access. Dr Schimizzi is a practicing rheumatologist, treasurer of the Coalition of State Rheumatology Organizations and co-convener of the Biologics Prescribers Collaborative. Distinguishable biosimilar naming was the top issue for […]


Click here for reuse options!
Copyright 2016 Biotechblog

%d bloggers like this: